Organ and prenatal toxicity of nonsteroidal anti-inflammatory drugs

• Authors: Katarzyna Dyndor , Wojciech Dworzanski , Małgorzata Pliszczynska-Steuden , Monika Cendrowska-Pinkosz , Tomasz Chroscicki , Przemyslaw Dyndor , Anna Dworzanska , Ewa Piasek , Piotr Piech , Marcin Ruchala , Katarzyna Golec , Teresa Hermanowicz-Dryka
• Languages of publication: EN

Abstracts

EN

Non-selective cyclooxygenase (COX) inhibitors, commonly referred to as nonsteroidal anti-inflammatory drugs (NSAIDs), are among the most taken pharmaceuticals. In adults, they can have a series of side effects, including especially gastroenterotoxicity, hepatotoxicity, nephrotoxicity, chondrotoxicity, and neurotoxicity, and they can induce allergic reactions. Any exacerbation of symptoms depends on the chemical structure of the drug, its dosage and duration of exposure, individual sensitivity, comorbidities and the degree of inhibition of basic COX isoenzymes - the constitutive (COX-2) and induced (COX-1) expressions. However, data on prenatal toxicity are inconsistent. Classic nonselective COX inhibitors do not result in an increase in the risk of developing significant congenital defects; however, if used in the late-pregnancy period, they can have an adverse effect on the foetus, by inducing the premature closure of the ductus arteriosus and by producing a tocolytic effect. Individual reports also indicate the increased risk of developing heart and anterior abdominal wall defects, as well as hypospadias.

Keywords

EN

NSAIDs; organ toxicity; developmental toxicity; reproductive toxicity

• Publisher: De Gruyter Open
• Journal: Current Issues in Pharmacy and Medical Sciences
• Year: 2015
• Volume: 28
• Issue: 3
• Pages: 200-203

Dates

published

1 - 9 - 2015

online

26 - 11 - 2015

accepted

26 - 8 - 2015

received

9 - 7 - 2015

Contributors

author

Katarzyna Dyndor

• Human Anatomy Department, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland

author

Wojciech Dworzanski

• Human Anatomy Department, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland

author

Małgorzata Pliszczynska-Steuden

• Human Anatomy Department, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland

author

Monika Cendrowska-Pinkosz

• Human Anatomy Department, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland

author

Tomasz Chroscicki

• Human Anatomy Department, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland

author

Przemyslaw Dyndor

• Chair and Department of Rehabilitation and Orthopaedics, Medical University of Lublin, Jaczewskiego 8, 20-950 Lublin, Poland

author

Anna Dworzanska

• Human Anatomy Department, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland

author

Ewa Piasek

• Human Anatomy Department, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland

author

Piotr Piech

• Human Anatomy Department, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland

author

Marcin Ruchala

• Human Anatomy Department, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland

author

Katarzyna Golec

• Human Anatomy Department, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland

author

Teresa Hermanowicz-Dryka

• Human Anatomy Department, Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland

References

• 1. Alano M.A. et al.: Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics, 107, 519-523, 2001.
• 2. Beck S.L.: Prenatal and postnatal assessment of maneb-exposed CD-1 mice. Reprod. Toxicol., 4, 83-290, 1990.
• 3. Bombardier C. et al.: VIGOR Study Group.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med., 343, 1520-1528, 2000.
• 4. Briggs GG. et al.: Drugs in pregnancy and lactation. A reference guide to fetal and neonatal risk. Lippincott Williams & Wilkins, Philadelphia, 2005.
• 5. Burdan F. et al.: Celosomy is associated with prenatal exposure to cyclo-oxygenase inhibitors. Pharmacol. Res., 53, 287-292, 2006.
• 6. Burdan F. et al.: Congenital ventricular septal defects and prenatal exposure to cyclooxygenase inhibitors. Braz. J. Med. Biol. Res., 39, 925-934, 2006.
• 7. Burdan F. et al.: Immuno-expression of the constitutive and inducible cyclo-oxygenase isoforms in maternal and fetal rat lungs. Ann. Univ. Mariae Curie Sklodowska Med. [Sectio D], 61, 330-334, 2006.
• 8. Burdan F. et al.: Localization of cyclo-oxygenase isoforms in maternal and offspring kidney during pregnancy and lactation. Ann. Univ. Mariae Curie Sklodowska Med. [Sectio D], 61, 326-329, 2006.
• 9. Burdan F. et al.: Prenatal effects of DuP-697 - the irreversible, highly selective cyclo-oxygenase-2 inhibitor. Reprod. Toxicol., 17, 413-419, 2003.
• 10. Burdan F. et al.: Skeletal developmental effects of selective and nonselective cyclo-oxygenase-2 inhibitors administered through organogenesis and fetogenesis in Wistar CRL.(WI)WUBR rats. Toxicology, 216, 204-223, 2005.
• 11. Burdan F. et al.: Prenatal tolerability of acetaminophen and other over-the-counter non-selective cyclo-oxygenase inhibitors. Pharmacol. Res., 64, 521-527, 2012.
• 12. Burdan F.: Comparison of developmental toxicity of selective and non-selective cyclo-oxygenase-2 inhibitors in CRL.(WI)WUBR Wistar rats - DFU and piroxicam study. Toxicology, 211, 12-25, 2005.
• 13. Burdan F.: Developmental effects of propyphenazone in analgesic and antipyretic combination with caffeine or paracetamol. Hum. Exp. Toxicol., 23, 235-244, 2004.
• 14. Burdan F.: Developmental toxicity evaluation of ibuprofen and tolmetin administered in triple daily doses to Wistar CRL.(WI) WUBR rats. Birth Defects Res Part B Dev Reprod. Toxicol., 71, 321-330, 2004.
• 15. Burdan F.: Intrauterine growth retardation and lack of teratogenic effects of prenatal exposure to the combination of paracetamol and caffeine in Wistar rats. Reprod. Toxicol., 17, 51-58, 2003.
• 16. Cannon C.P. et al.: Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis, in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet, 368, 1771-1781, 2006.
• 17. Carter A.M.: Evolution of factors affecting placental oxygen transfer. Placenta, 2009, 19-25.[WoS]
• 18. Chaiamnuay S. et al.: Risks versus benefits of cyclo-oxygenase-2- selective nonsteroidal anti-inflammatory drugs. Am. J. of Health- System Pharm., 19, 1848-1851, 2006.
• 19. Chernoff N. et al.: Significance of supernumerary ribs in rodent developmental toxicity studies: postnatal persistence in rats and mice. Fundam. Appl. Toxicol., 17, 448-453, 1991.[Crossref]
• 20. Cook J.C. et. al.: Analysis of the nonsteroidal anti-inflammatory drug literature for potential developmental toxicity in rats and rabbits. Birth. Defects Res. B. Dev. Reprod. Toxicol., 68, 5-26, 2003.
• 21. Dingle J.T. The effects of NSAID on the matrix human articular cartilages. Z. Rheumatol., 58, 125-129, 1999.
• 22. Fritz H.: Prenatal ossification in rabbits as indicative of fetal maturity. Teratology. 11. 313-319, 1975.[Crossref]
• 23. Hippisley-Cox J., Coupland C.: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: population based nested casecontrol analysis. Br. Med. J., 330, 1366, 2005.
• 24. Khan K.N. et al.: Expression of cyclo-oxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure and nephropathy. Ren Fail., 23, 321-330, 2001.
• 25. Khera K.S.: Common fetal aberrations and their teratologic significance: a review. Fundam. Appl. Toxicol., 1, 13-18, 1981.
• 26. Mandell B.F.: General tolerability and use of nonsteroidal antiinfammatory drugs. Am. J. Med., 107, 72-76, 1999.
• 27. Mardini I.A. Fitzgerald G.A.: Selective inhibitors of cyclooxygenase-2. Am. Soci. Pharm. Exp. Therap., 1, 30-43, 2001.
• 28. Markowitz G.S. et al.: Membranous glomerulopathy and acute interstitial nephritis fallowing treatment with celecoxib. Clin. Nephrol., 59, 137-142, 2003.
• 29. Radi Z.A., Khan N.K.: Effects of cyclo-oxygenase inhibition on the gastrointestinal tract. Exp. Toxicol. Pathol., 58, 163-173, 2006.
• 30. Østensen M., et al. Pregnancy and reproduction in autoimmune rheumatic diseases. Rheumatology (Oxford)., 50, 657-664, 2011.[WoS]
• 31. alhab A.S. et al.: Meloxicam inhibits rabbit ovulation. Contraception. 63, 329-333, 2001.
• 32. Sanchez-Borges M.: Tolerability to new COX-2 inhibitors in NSAIDsensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol., 87, 201-204, 2001.
• 33. angha R.K. et al.: Immunohistochemical localization, messenger ribonucleic acid abundance, and activity of 15-hydroxyprostaglandin dehydrogenase in placenta and fetal membranes during term and preterm labor. J. Clin. Endocrinol. Metab., 78, 982-989, 1994.
• 34. Scheaffer C. et al.: Drugs during pregnancy and lactation. 2 ed. (2007). Academic Press; Londyn.
• 35. Scialli A.R. et al.: Communicating risks during pregnancy: a workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res. A. Clin. Mol. Teratol., 70, 7-12, 2004.
• 36. Sibal B.M., et al.: Low-dose aspirin in pregnancy. Obstet. Gynecol., 74, 551-557, 1989.[WoS]
• 37. Silverstein F.E. et all.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 284, 1247-1255, 2000.
• 38. Szczeklik A. et al.: Safety of a specific COX-2 inhibitor in aspirin induced asthma. Clin. Exp. Allergy., 31, 219-225, 2001.
• 39. Torfs C.P. et al.: Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology, 54, 84-92, 1996.
• 40. Vermillion S.T. et al.: The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am. J. Obstet. Gynecol., 177, 256-261, 1997.
• 41. Werler M.M., et al.: Use of over-the-counter medications during pregnancy. Am. J. Obstet. Gynecol., 193, 771-777, 2005.
• 42. Yasuda S. et al.: Placental folate transport during pregnancy. Biosci. Biotechnol. Biochem., 72, 2277-2284, 2008.[WoS]
• 43. Zimmerman H.J. Ishak K.G. General aspects of drug induced liver disease. Gastroenterol. Clin. North Am., 24, 793-757, 1995.

Identifiers

DOI

10.1515/cipms-2015-0072